Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Gynaecological Cancers Congress 2022

GSK - Using biomarkers to guide targeted therapy in gynaecological cancers

How and when should HRD testing guide treatment for 1L advanced ovarian cancer?

Date

17 Jun 2022

Session

GSK - Using biomarkers to guide targeted therapy in gynaecological cancers

Presenters

Christoph Grimm

Authors

C. Grimm1, A. Oaknin2, X. Matias-Guiu3, G. Valabrega4

Author affiliations

  • 1 Universitätskliniken der MedUni Wien - AKH Wien, 1090 - Vienna/AT
  • 2 Vall d'Hebron University Hospital, Barcelona/ES
  • 3 University of Lleida, Hospitalet de Llobregat/ES
  • 4 IRCCS - Istituto di Candiolo - FPO, Candiolo/IT

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and introduction

Presenter: Ana Oaknin

Session: GSK - Using biomarkers to guide targeted therapy in gynaecological cancers

Resources:

Webcast

Q&A from audience

Presenter: The Panelists

Session: GSK - Using biomarkers to guide targeted therapy in gynaecological cancers

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.